Another ongoing clinical trial (NCT06710197) is assessing changes in the TME after 14 days of preoperative IL-1-inhibiting therapy (Anakinra) in patients with early BC (including TNBC and ER-low positive tumors). The gene discussed is IL1B; the disease is breast cancer.